{
  "ticker": "ALA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02961346",
  "id": "02961346",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250624",
  "time": "0919",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250624/pdf/06l1dww32pq8fd.pdf",
  "summary": "### Summary of ASX Announcement (ALA \u2013 Arovella Therapeutics Limited)  \n\n- **Notice under Section 708A(5)(e) of the Corporations Act 2001**  \n  - **750,000 ordinary shares (ALA)** issued without disclosure under Part 6D.2.  \n  - Compliance with Chapter 2M (financial reporting) and continuous disclosure obligations confirmed.  \n  - **No material undisclosed information** identified as per statutory requirements.  \n\n**No other material trading or capital markets information identified**.  \n\n*(Note: Company overview and forward-looking statements omitted as non-material for trading decisions.)*",
  "usage": {
    "prompt_tokens": 1318,
    "completion_tokens": 128,
    "total_tokens": 1446,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-23T23:28:00.791906"
}